Mirum Pharmaceuticals, Inc. (MIRM): רווח נקי למניה ב-12 החודשים האחרונים

The fundamental EPS TTM metric demonstrates the profitability dynamics of Mirum Pharmaceuticals (MIRM), where the -15.17 level reflects the current earnings magnitude. Mirum Pharmaceuticals is expanding its footprint in Asia and Europe through global partners and pediatric alliances. The business develops high-margin drugs for rare liver pathologies, betting on monopoly status following certification. Production relies on reliable contract manufacturing capacities with optimized logistics.
MIRM (Mirum Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For Mirum Pharmaceuticals (MIRM), which invests in the bioengineering of targeted drugs against cholestasis, the trend of trailing twelve-month earnings per share serves as an indicator of the efficiency in monetizing its scientific and technological potential. This metric is calculated as the ratio of total net income over the last 12 months to the number of shares outstanding, allowing the investor to assess the real return on each share and the fundamental stability of the business.